Efletirizine

Drug Profile

Efletirizine

Alternative Names: UCB 28754

Latest Information Update: 02 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UCB
  • Class Acetates; Antiallergics; Antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Seasonal allergic rhinitis; Urticaria

Most Recent Events

  • 07 Jun 2005 Discontinued - Phase-II for Seasonal allergic rhinitis in USA (Intranasal)
  • 11 Feb 2005 UCB has completed a proof of concept trial of the once-daily formulation of efletirizine
  • 06 Jan 2004 UCB has completed phase III trials of twice-daily efletirizine in seasonal allergic rhinitis and urticaria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top